Skip to main content
52°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
108.70
-1.05 (-0.96%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
93
94
Next >
Peering Into Merck & Co's Recent Short Interest
January 10, 2024
Via
Benzinga
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
Demystifying Merck & Co: Insights From 9 Analyst Reviews
January 09, 2024
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
P/E Ratio Insights for Merck & Co
January 05, 2024
Via
Benzinga
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Via
Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
January 08, 2024
Via
Benzinga
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
January 08, 2024
The year's biggest medical conference kicked off with a melee of buyout news.
Via
Investor's Business Daily
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
January 08, 2024
Shares shot 7% higher in the first week of 2024 as excitement grows for its late-stage pipeline.
Via
Investor's Business Daily
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
January 08, 2024
Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share.
Via
InvestorPlace
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
January 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Why Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?
January 08, 2024
Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ:
Via
Benzinga
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
January 08, 2024
These four names span different sectors, but all underperformed in 2023. Is it time to be a contrarian and pick up bargains on the discount aisle?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Wall Street's Top 10 Stock Calls This Week - Saturday, Jan. 6
January 06, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 2-5.
Via
Talk Markets
Are defensive sectors ready to outshine growth in 2024?
January 06, 2024
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.
Via
MarketBeat
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Healthcare Champions Kick Off 2024
January 05, 2024
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly...
Via
Benzinga
Exposures
COVID-19
Dry January Investing: Trading Pints For Portfolio Growth
January 05, 2024
Around 15% of Americans said they were planning to participate in Dry January — a month of abstinence from alcohol — according to a survey.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
3 reasons 2024 Moderna shareholders may party like it's 2021
January 05, 2024
With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains.
Via
MarketBeat
Exposures
COVID-19
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
January 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
Stocks Edge Higher, Nasdaq Looks To Snap Skid
January 04, 2024
Stocks are attempting to regain their 2023 form today.
Via
Talk Markets
McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'
January 04, 2024
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK)
Via
Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
AMD To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Thursday
January 04, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
93
94
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.